🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Deferasirox

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  2. Defibrotide

    Jazz Pharmaceuticals Ireland Limited

    Transplant-Associated Thrombotic Microangiopathy

    phase 2 small molecule terminated

    1 trial

  3. Denosumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Dental stent

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  5. Dermatophagoides Farinae Drops Group 1

    The First People's Hospital of Lianyungang

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  6. Determine the ED50 and ED95 of esketamine

    The First People's Hospital of Lianyungang

    Intrauterine Polyp

    phase 2 small molecule active

    1 trial

  7. Dexamethason 4 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, CRISANTASPASE, Dexamethason 0,5 mg JENAPHARM®, Vincristine Sulfate 1 mg/ml solution for injection, Oncaspar 750 U/ml powder for solution for injection/infusion., Dexamethasone 3.3 mg/mL Solution for injection, MITOXANTRONE HYDROCHLORIDE, BESPONSA 1 mg powder for concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  8. Dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    ITP

    phase 2 small molecule active

    1 trial

  9. Dexamethasone

    The First People's Hospital of Lianyungang

    Precursor B-Cell Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  10. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  11. Dexamethasone Combined with romiplostim N01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  12. Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets, Diluent for REGN5458, Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, Dermodrin 30 mg/2 ml soluție injectabilă, Dexamethasone 4 mg tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Linvoseltamab

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  13. Dexmedetomidine injection

    Sana Biotechnology

    Post Spinal Shivering

    phase 2 small molecule active

    1 trial

  14. Dimethyl fumarate

    Xuanwu Hospital, Beijing

    Intracerebral Hemorrhage

    phase 2 small molecule terminated

    1 trial

  15. Dinutuximab

    Children's Hospital of Fudan University

    High Risk Neuroblastoma

    phase 2 mab active

    1 trial

  16. Dipraglurant

    Addex Therapeutics

    Blepharospasm

    phase 2 small molecule completed

    1 trial

  17. Disitamab Vedotin

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  18. Disitamab Vedotin (RC48)

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  19. Docetaxel

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  20. Donafenib + Envafolimab

    Anhui Provincial Hospital

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  21. Donepezil Hydrochloride

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Radiation Injuries

    phase 2 small molecule active

    1 trial

  22. Dose-attenuated IST and Hetrombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sever Aplastic Anaemia

    phase 2 small molecule active

    1 trial

  23. Dostarlimab

    Hospital Authority, Hong Kong

    Female

    phase 2 small molecule active

    1 trial

  24. Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)

    Hospital Authority, Hong Kong

    Benign Prostatic Hyperplasia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources